Osceola, WI – Surpass, Inc. (“Surpass”), announced today the acquisition of LyChron, LLC (“LyChron”), expanding its capacity to serve the medical device and preclinical research community. The new California entity will operate as Surpass-Silicon Valley, LLC.
Surpass President & CEO, Liann Johnson, expressed her confidence over bringing the two organizations together, “Given significant synergies in the competencies at each site, we now have the opportunity to identify best practices and implement them across the organizations to assure that our clients receive the highest quality preclinical study experience available today.”
The operating environment for Contract Research Organizations has become increasingly challenging. Johnson continued, “Globally we are facing a strained economic landscape, and our clients, medical device and biopharmaceutical companies, are dealing with regulatory uncertainties and profit erosion.” Through the acquisition, Surpass clients will benefit by leveraging the combined resources, capacity and expertise from the earliest feasibility/proof-of-concept to pivotal GLP-compliant studies.
About Surpass
Founded in 2006, Surpass is a leading preclinical Contract Research Organization offering non-GLP and GLP preclinical research studies that require surgical or interventional approaches to evaluate the safety and efficacy of medical devices, drugs, and biologics. Based in Osceola, WI, the facility serves a range of medical specialties including cardiovascular, peripheral vascular, neurovascular, wound healing, orthopedics, and general surgery. For more information please visit www.surpassinc.com.
About LyChron
LyChron was founded in 2000 by a team of scientists and physicians and provides proof-of-concept, feasibility, prototype evaluation, validation, and GLP safety preclinical studies, as well as facilitating physician and clinical training, refining study designs, and developing novel disease models. Located in Mountain View, CA, LyChron is experienced with the evaluation of medical devices, gene or cell therapies, and pharmacological agents intended for human and veterinary clinical trials and ultimate market release. For more information please visit www.lychron.com.
